ArticleChemistry & biodiversity2026
Elucidating the Mechanism of Modified Yiguanjian against Anti-Tuberculosis Drug-Induced Liver Injury via Integrated Pharmacology and Metabolomics.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the therapeutic effects and molecular mechanisms of Modified Yiguanjian (MYGJ) in treating anti-tuberculosis drug-induced liver injury (ATB-DILI). ATB-DILI is a serious side effect of TB treatment, often leading to liver damage, drug resistance, or failure. The research integrated serum pharmacochemistry, network pharmacology, and metabolomics to uncover MYGJ's hepatoprotective mechanisms. Using ultra-high-performance liquid chromatography coupled with quadrupole-electrostatic field orbitrap mass spectrometry, the study identified 11 prototype compounds of MYGJ in blood serum, including Apigenin and Lonicerin. The ATB-DILI mouse model induced by isoniazid, rifampicin, and pyrazinamide showed MYGJ's effectiveness in reducing liver enzyme levels (alanine aminotransferase, aspartic transaminase, and alkaline phosphatase), improving histopathology, and lowering pro-inflammatory cytokines (tumor necrosis factor-α, interleukin [IL]-1β, and IL-6). Network pharmacology identified 128 shared targets, including key molecules like TP53 and AKT1, and suggested tyrosine and purine metabolism as critical pathways. Metabolomics identified 95 altered metabolites, with MYGJ reversing 38 of them. Molecular docking confirmed strong binding between MYGJ compounds and targets like adenosine deaminase and myeloperoxidase. Overall, MYGJ alleviated ATB-DILI through multi-target, multi-pathway actions, demonstrating its potential for liver protection in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.